Home > Insider Trading > Filing (0001140361-14-031043)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1581720	Loxo Oncology Inc.	LOXO	Pharmaceutical Preparations (2834)	462996673

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1120478	Md A Dov Goldstein	C/O Loxo Oncology, Inc. One Landmark Square, Suite 1122 Stamford CT 06901	Cfo And Treasurer	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-08-06	2,850,709	$0.00	3,039,416	No	4	C	Indirect	Held by Aisling Capital III, LP
Common Stock	Acquisiton	2014-08-06	413,077	$13.00	3,452,493	No	4	P	Indirect	Held by Aisling Capital III, LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	Held by Aisling Capital III, LP
No	4	P	Indirect	Held by Aisling Capital III, LP

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2014-08-06	2,343,749	$0.00	2,343,749	$0.00
Common Stock	Series B Preferred Stock	Disposition	2014-08-06	506,960	$0.00	506,960	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	22,656	Direct

Footnotes

In connection with the consummation of the Issuer's initial public offering on August 6, 2014, each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration. All shares of Common Stock issued upon conversion were aggregated.
The securities are directly held by Aisling Capital III, LP ("Aisling"), and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, and Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP. Dr. Goldstein is an Operating Partner of Aisling GP. Aisling GP has established an investment committee that has voting and dispositive power over the shares held by Aisling, of which Dr. Goldstein is a member. Dr. Goldstein disclaims beneficial ownership of these shares held directly by Aisling and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or any other purposes, except to the extent of his pecuniary interest therein.
None.